Special Issue "Novel Vaccine Technologies and Platforms to Protect from Infectious Diseases"

A special issue of Biologics (ISSN 2673-8449).

Deadline for manuscript submissions: 15 October 2023 | Viewed by 264

Special Issue Editors

Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, SK, Canada
Interests: veterinary vaccines; adenovirus; porcine reproductive and respiratory virus
Special Issues, Collections and Topics in MDPI journals
1. Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada
2. Research and Development Department, Precision NanoSystems Inc., Vancouver, BC, Canada
Interests: antiviral vaccines; non-viral vaccine delivery and gene editing, expression, and silencing using non-viral vectors or lipid nanoparticles

Special Issue Information

Dear Colleagues,

Vaccines are crucial to maintaining public health, and they have demonstrated cost-effective benefits in protecting both humans and animals from infectious diseases. The majority of vaccines available today rely either on the attenuation or inactivation of infectious agents. However, both techniques have their limitations and potential associated problems. To overcome these problems, scientists have been working on the development of new vaccine technologies and platforms. These include subunit and virus-like particle (VLP) vaccines, synthetic peptide vaccines, polysaccharide, and polysaccharide-conjugated vaccines, bacterial and viral-vector-based vaccines, and DNA- as well as mRNA-based vaccines. Advances in novel vaccine technologies allowed us to quickly respond to the global epidimic caused by SARS-CoV-2; adenovirus-based and mRNA-based vaccines against SARS-CoV-2 were quickly developed and approved in many countries around the world. In the veterinary field, vaccines based on baculovirus or alphavirus vector platform technology can be quickly produced to target agents causing emerging diseases if traditional vaccines are ineffective. This Special Issue of Biologics will cover new research and developments in the area of new vaccine technologies and platforms.

Dr. Alexander Zakhartchouk
Dr. Sams Sadat
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biologics is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • virus-like particles
  • polysaccharide vaccine
  • next-generation vaccines
  • viral or bacterial vectored vaccine
  • replicon-based vaccine
  • DNA vaccine
  • mRNA vaccine

Published Papers

This special issue is now open for submission.
Back to TopTop